JAK1 and atopic eczema: In Japan, the most recent guidance for the use of oral JAKi in the treatment of AD recommended abrocitinib based on the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) COMPARE (NCT037204700), JADE TEEN (NCT03796676), and JADE Mono‐2 (NCT03575871) trial results.11